Beta Bionics Q2 sales beat estimates on pharmacy channel growth
BBNX•Growth drivers in the quarter
- PBP channel net sales rose 153% year over year, contributing to overall revenue growth.
- New patient starts increased by at least 10% but less than 20% sequentially versus Q1 2026, with 69% coming from multiple daily injections.
- Gross margin was 59.0%, up 524 basis points year over year.
Analyst coverage and price target
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the advanced medical equipment & technology peer group is "buy".
- Wall Street's median 12-month price target for Beta Bionics Inc is $20.00, about 26.6% above its July 28 closing price of $15.80.
Q2 sales and profitability details
- Beta Bionics' Q2 net sales rose 38% year over year, beating analyst expectations.
- Q2 adjusted EBITDA loss widened year over year but was narrower than analyst expectations.
- The company improved gross margin to 59% and maintained full-year revenue guidance.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net sales | Beat | $32.01 mln | $31.44 mln (10 Analysts) |
| Q2 Loss Per Share |
